

Antengene announces approval of first Ph I Trial of ATG-017

13 August 2020 | News

ATG-017 is a potent and selective small-molecule extracellular signal--regulated kinase 1 and 2 (ERK1/2) inhibitor



ANTENGENE

—— 德琪医药 ——

Shanghai-based Antengene Corporation, leading innovative hematology and oncology-focused biopharmaceutical company, announced recently the authorization of the first-in-human trial of ATG-017 (ERASER trial) by the Australian Therapeutic Goods Administration (TGA). ATG-017 is a potent and selective small-molecule extracellular signal--regulated kinase 1 and 2 (ERK1/2) inhibitor. The study will enroll patients with advanced solid tumors and hematological malignancies.

ATG-017 is an oral, potent and highly selective inhibitor of ERK1/2, which are related protein-serine/ threonine kinases that function as the terminal kinases in the RAS-RAF-MEK-ERK signal transduction cascade. This pathway participates in the control of numerous processes which include apoptosis, cell proliferation, and cellular immune response. In preclinical studies, ATG-017 has proven to regulate a large variety of cellular processes by targeting ERK1/2 and has shown to be effective in inhibiting the viability of tumor cell lines in vitro as well as the tumor growth in vivo.

In November 2019, Antengene entered into a licensing agreement with AstraZeneca (LSE/STO/NYSE: AZN) under which Antengene has been granted the exclusive global rights to further develop, manufacture and commercialize AZD0364 (ATG-017). ATG-017 is currently being studied in clinical trials for the treatment of various solid tumors and hematological malignancies.